Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 15/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 15/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 15/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 15/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 13/20 | 0.39 |
| ▸ | BPTF | Q12830 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19756453 | 1.00 | CHRNB2 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4CCR5 | |
| SCHEMBL12250822 | 1.00 | CHRNB2 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4CCR5 | |
| SCHEMBL27380454 | 1.00 | CHRNB2 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4CCR5 | |
| SCHEMBL22827192 | 1.00 | CHRNB2 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4CCR5 | |
| SCHEMBL10176085 | 0.84 | CHRNB2 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4CCR5 | |
| SCHEMBL21210559 | 0.84 | CHRNB2 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4CCR5 | |
| SCHEMBL21786928 | 0.84 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL12209130 | 0.84 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL19558161 | 0.81 | HTR2C (0.31) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Trifluoroacetic Acid SCHEMBL3338287 | 0.81 | CHRNB2 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365526-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC (US) | 2023-11-16 | — | — | US | disclosed |
| EP-4253376-A1 | SALT AND CRYSTAL FORM OF NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023125877-A1 | TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023125935-A1 | BENZOPYRIDINE DERIVATIVE REGULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023122298-A1 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP28 AND/OR USP25 TARGETING LIGANDS | Stablix, Inc. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230112485-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| WO-2023018648-A1 | PHENOL DERIVATIVES FOR USE IN THE MODULATION OF BRM | GENENTECH, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| US-20220411372-A1 | SMALL-MOLECULE INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2022-12-29 | — | — | US | disclosed |
| US-11382918-B2 | Methods for treating Huntington's Disease | PTC THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-9000172-B2 | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-07 | — | — | US | disclosed |
| US-20150080413-A1 | Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones | Janssen Sciences Ireland Unlimited Company (IE) | 2015-03-19 | — | — | US | disclosed |
| US-20150080413-A1 | Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones | Janssen Sciences Ireland Unlimited Company (IE) | 2015-03-19 | — | — | US | disclosed |
| US-8906923-B2 | Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN R&D IRELAND (IE) | 2014-12-09 | — | — | US | disclosed |
| US-8906923-B2 | Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN R&D IRELAND (IE) | 2014-12-09 | — | — | US | disclosed |
| US-20140296214-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-10-02 | — | — | US | disclosed |
| US-20140171451-A1 | Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN R&D IRELAND (IE) | 2014-06-19 | — | — | US | disclosed |
| US-20140171451-A1 | Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN R&D IRELAND (IE) | 2014-06-19 | — | — | US | disclosed |
| WO-2013021054-A1 | ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | JANSSEN R&D IRELAND (IE) | 2013-02-14 | — | — | WO | disclosed |
| US-20080085884-A1 | Melanin Concentrating Hormone Receptor-1 Antagonist Pyridinones | PFIZER INC | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296214-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, KLKB1 | CHRNB2 4670/4885CHRNB4 4618/4885CHRNA3 4458/4885 |
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | RBM17, HNRNPA1, HNRNPAB | CHRNB2 2938/4885CHRNB4 3136/4885CHRNA3 3072/4885 |
| US-20220411372-A1 | SMALL-MOLECULE INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | BCL9, BCL9L, BCL6 | CHRNB2 3935/4885CHRNB4 4105/4885CHRNA3 4207/4885 |
| US-20150080413-A1 | Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones | ECI1, ALPI, PREP | CHRNB2 4880/4885CHRNB4 4869/4885CHRNA3 4707/4885 |
| US-20230112485-A1 | THERAPEUTIC COMPOUNDS | BRDT, BRPF3, SNRPE | CHRNB2 1470/4885CHRNB4 2010/4885CHRNA3 2216/4885 |
| US-20140171451-A1 | Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones | ECI1, ALPI, PREP | CHRNB2 4880/4885CHRNB4 4869/4885CHRNA3 4707/4885 |
| US-20080085884-A1 | Melanin Concentrating Hormone Receptor-1 Antagonist Pyridinones | MCHR1, MCHR2, MC1R | CHRNB2 726/4885CHRNB4 942/4885CHRNA3 761/4885 |
| US-20230365526-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | SNRPA, RBM17, SNRPB2 | CHRNB2 2637/4885CHRNB4 2937/4885CHRNA3 2727/4885 |
| US-11382918-B2 | Methods for treating Huntington's Disease | HTT, HYPK, PARK7 | CHRNB2 384/4885CHRNB4 273/4885CHRNA3 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.